Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 20/20 | 0.63 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771337 | 1.00 | ECE1 (0.63) | ECE1MMEACE | |
| SCHEMBL7020540 | 0.88 | ECE1 (0.49) | ECE1MMEACE | |
| SCHEMBL6775855 | 0.83 | ECE1 (0.66) | ECE1MMEACE | |
| SCHEMBL6776406 | 0.82 | ECE1 (0.79) | ECE1MMEACE | |
| SCHEMBL6774836 | 0.82 | ECE1 (0.79) | ECE1MMEACE | |
| SCHEMBL6771282 | 0.81 | ECE1 (0.80) | ECE1MMEACE | |
| SCHEMBL6771288 | 0.81 | ECE1 (0.80) | ECE1MMEACE | |
| SCHEMBL6774659 | 0.81 | ECE1 (0.70) | ECE1MMEACE | |
| SCHEMBL6774665 | 0.81 | ECE1 (0.70) | ECE1MMEACE | |
| SCHEMBL6775845 | 0.80 | ECE1 (0.66) | ECE1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716852-B2 | FOR THERAPY OF ARTERIAL HYPERTENSION AND CARDIOVASCULAR DISEASES | LES LABORATORIES SERVIER (FR) | 2004-04-06 | — | — | US | disclosed |
| EP-1255757-B1 | AMINO ACID DERIVATIVES AND USE THEREOF AS NEP, ACE AND ECE INHIBITORS | INST NAT SANTE RECH MED (FR) | 2003-06-18 | — | — | EP | disclosed |
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | LES LABORATOIRES SERVIER (FR) | 2003-03-20 | — | — | US | disclosed |
| EP-1255757-A1 | AMINO ACID DERIVATIVES AND USE THEREOF AS NEP, ACE AND ECE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060822-A1 | AMINO ACID DERIVATIVES AND USE THEREOF AS NEP, ACE AND ECE INHIBITORS | INSTITUT NATIONAL DE LA RECHERCHE MEDICALE INSERM (FR) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | MME, ACE, ECE1 | ECE1 3/4885MME 1/4885ACE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.